Saturday, 10 October 2026European Markets

PHAROL Stock Impressive Rise On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with PHAROL (PHR.LS) jumping 12.32% to €0.05 on Thursday while PSI dropped 0.19% to €6,589.57.

PHAROL's last close was €0.04, 46.45% under its 52-week high of €0.08.

About PHAROL

Pharol, SGPS S.A., through its investment in Oi, S.A., provides telecommunications services in Brazil. The company was formerly known as Portugal Telecom, SGPS, SA and changed its name to Pharol, SGPS S.A. in May 2015. Pharol, SGPS S.A. was incorporated in 1994 and is headquartered in Lisbon, Portugal.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -3.04%.

Volatility

PHAROL's last week, last month's, and last quarter's current intraday variation average was 3.57%, 0.24%, and 1.43%.

PHAROL's highest amplitude of average volatility was 3.57% (last week), 1.97% (last month), and 1.43% (last quarter).

More news about PHAROL (PHR.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com